GenSight Biologics
Edit

GenSight Biologics

https://www.gensight-biologics.com/
Last activity: 28.02.2023
Categories: ITInformationHealthTechClinicBioTechAppAdTechMedtechProductTechnology
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Followers
4.68K
Website visits
10.3K /mo.
Mentions
40
Location: France, Ile-de-France
Employees: 11-50
Total raised: $149.44M
Founded date: 2013
Twitter
Facebook
LinkedIn
Email

Investors 5

Funding Rounds 4

DateSeriesAmountInvestors
10.06.2021-$36.4M-
29.03.2021-$35.38M-
23.07.2015Series B$36M-
08.04.2013Series A$41.66M-

Mentions in press and media 40

DateTitleDescriptionSource
28.02.2023GenSight Biologics Raises Awareness of Leber Hereditary Opti...GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene th...aithority....
20.01.2022GenSight Biologics S A : Corporate presentation, January 202...Corporate Presentation January 2022 A LEADING Gene Therapy BIOTECHNOLOGY COMPANY GENSIGHT-BIOLOGI...marketscre...
29.03.2021GENSIGHT BIOLOGICS S.A. GenSight Biologics S A : successful...Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), ...marketscre...
26.03.2021GENSIGHT BIOLOGICS S.A. GenSight Biologics S A : launches a...Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), ...marketscre...
30.07.2020GENSIGHT BIOLOGICS S.A. GenSight Biologics S A : 2020 Half-...HALF-YEAR FINANCIAL REPORT JUNE 30, 2020 TABLE OF CONTENTS CONDENSED HALF-YEAR CONSOLIDATED FINAN...marketscre...
04.04.2018A gene ther­a­py mys­tery? Gen­Sight blast­ed as 1st PhI­II ...Gen­Sight has a gene ther­a­py mys­tery on its hands, which is about the last thing it want­ed at th...endpts.com...
23.06.2017Mer­ck KGaA gets a thumbs up for once-dead MS drug; Aveo sha...→ Cladrib­ine is back. Once giv­en up for dead by Mer­ck KGaA, the mul­ti­ple scle­ro­sis drug has b...endpts.com...
23.06.2017Novartis-backed GenSight gets cash for gene therapy launchGenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy G...fiercebiot...
23.07.2015Daily funding roundup - July 23, 2015Flipboard raised $50M; Notion Capital launched $120M; CarPrice closed $40M CarPrice wants to be the...vator.tv/n...
23.07.2015GenSight Biologics Completes $36M Series B FinancingGenSight Biologics S.A., a Paris, France-based clinical-stage biotechnology company, completed a $36...finsmes.co...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In